Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
- 3 January 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (43)
- https://doi.org/10.1126/sciimmunol.aay1863
Abstract
PD-1, a T cell checkpoint receptor and target of cancer immunotherapy, is also expressed on myeloid cells. The role of myeloid-specific versus T cell–specific PD-1 ablation on antitumor immunity has remained unclear because most studies have used either PD-1–blocking antibodies or complete PD-1 KO mice. We generated a conditional allele, which allowed myeloid-specific (PD-1f/fLysMcre) or T cell–specific (PD-1f/fCD4cre) targeting of Pdcd1 gene. Compared with T cell–specific PD-1 ablation, myeloid cell–specific PD-1 ablation more effectively decreased tumor growth. We found that granulocyte/macrophage progenitors (GMPs), which accumulate during cancer-driven emergency myelopoiesis and give rise to myeloid-derived suppressor cells (MDSCs), express PD-1. In tumor-bearing PD-1f/fLysMcre but not PD-1f/fCD4cre mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell–specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1–deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.Keywords
This publication has 72 references indexed in Scilit:
- Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axisJCI Insight, 2013
- CD14+S100A9+ Monocytic Myeloid-derived Suppressor Cells and Their Clinical Relevance in Non–Small Cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2012
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissueNature Protocols, 2012
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in miceJCI Insight, 2011
- Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune responseNature Reviews Immunology, 2011
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSFEuropean Journal of Immunology, 2009
- PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsisProceedings of the National Academy of Sciences of the United States of America, 2009
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activityBlood, 2008